Sarepta Therapeutics | SRPT - Current Assets


Sarepta Therapeutics reported $2.31B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Agios Pharmaceuticals USD 717.67M 117.18M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
Amgen USD 31.48B 2.42B Mar/2026
BioCryst Pharmaceuticals USD 373.62M 30.72M Mar/2026
Biogen USD 7.31B 1.88B Jun/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Capricor Therapeutics USD 283.09M 39.85M Mar/2026
Daiichi Sankyo JPY 2.23T 91.92B Jun/2026
Eli Lilly USD 54.84B 794M Mar/2026
Gilead Sciences USD 18.64B 1.25B Mar/2026
Incyte USD 6.03B 542.31M Jun/2026
Insmed USD 1.61B 181.04M Mar/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
Moderna USD 5.82B 45M Jun/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
Novavax USD 850.82M 127.46M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
PTC Therapeutics USD 2.62B 363.36M Jun/2026
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 31.52B 1.36B Jun/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Tectonic Therapeutic USD 239.89M 17.47M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026